	Document Owner Department: QC	BT-SPEC-0745
		Page 1 of 2
OXOID QUALITY ASSURANCE PRODUCT SPECIFICATION		
MOXIFLOXACIN MXF5 CT1633B		

## Product Details

<b>Product Name</b>	MOXIFLOXACIN
<b>Disc Code</b>	MXF5
<b>Disc Concentration</b>	5µg
<b>CT Code</b>	CT1633B
<b>Shelf Life (years)</b>	2
<b>CLSI Recommended Concentration</b>	Yes
<b>EUCAST Recommended Concentration</b>	Yes

## Microbiological Performance Criteria

CLSI		
Organism	ATCC/NCTC Number	Range (mm)
<i>Escherichia coli</i>	ATCC® 25922	28 – 35
<i>Staphylococcus aureus</i>	ATCC® 25923	28 – 35
<i>Pseudomonas aeruginosa</i>	ATCC® 27853	17 – 25
<i>Haemophilus influenzae</i>	ATCC® 49247	31 – 39
<i>Streptococcus pneumoniae</i>	ATCC® 49619	25 – 31

EUCAST		
Organism	ATCC/NCTC Number	Range (mm)
<i>Escherichia coli</i>	ATCC® 25922	28 – 35
<i>Staphylococcus aureus</i>	ATCC® 29213	25 – 31
<i>Streptococcus pneumoniae</i>	ATCC® 49619	24 – 30
<i>Haemophilus influenzae</i>	ATCC® 49766	30 – 36


## References

For recommended concentrations, the zone limits are in accordance with the current performance standards for antimicrobial disc susceptibility tests;

- CLSI: M100 Performance standards for antimicrobial susceptibility testing
- EUCAST Routine and extended internal quality control for MIC determination and disc diffusion as recommended by EUCAST

Other additional challenging strains may be employed.

The information given above is believed to be correct, however both the information and the product are offered without warranty for any specific use, other than that specified in the current Oxoid manual.

	Document Owner Department: QC	BT-SPEC-0745
		Page 2 of 2
OXOID QUALITY ASSURANCE PRODUCT SPECIFICATION		
MOXIFLOXACIN MXF5 CT1633B		

## Revision History

Section / Step	Description of Change	Reason for Change	Reference
EUCAST table	Addition of <i>Haemophilus influenzae</i> ATCC® 49766	Change control	BT-CC-3173